Integer (NYSE:ITGR) had its price objective cut by research analysts at Argus from $90.00 to $4.29 in a report released on Wednesday, June 5th, The Fly reports. The firm currently has an “average” rating on the medical equipment provider’s stock. Argus’ price objective would suggest a potential downside of 94.89% from the company’s current price. The analysts noted that the move was a valuation call.
A number of other research firms have also recently commented on ITGR. Zacks Investment Research upgraded shares of Integer from a “hold” rating to a “strong-buy” rating and set a $101.00 price target on the stock in a report on Tuesday, February 26th. Royal Bank of Canada raised their target price on shares of Integer from $84.00 to $92.00 and gave the stock a “sector perform” rating in a report on Monday, February 25th. Finally, ValuEngine downgraded shares of Integer from a “buy” rating to a “hold” rating in a research report on Thursday, April 18th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $74.66.
NYSE:ITGR traded down $1.02 during trading hours on Wednesday, hitting $83.92. 578,100 shares of the company were exchanged, compared to its average volume of 246,922. The business’s fifty day moving average is $75.26. The company has a market cap of $2.77 billion, a PE ratio of 22.08 and a beta of 0.84. The company has a quick ratio of 1.49, a current ratio of 2.55 and a debt-to-equity ratio of 0.84. Integer has a one year low of $63.50 and a one year high of $92.61.
In other news, Director James F. Hinrichs acquired 3,750 shares of Integer stock in a transaction that occurred on Thursday, May 23rd. The stock was purchased at an average price of $68.47 per share, for a total transaction of $256,762.50. Following the purchase, the director now directly owns 6,549 shares in the company, valued at approximately $448,410.03. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 2.24% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the business. Optimum Investment Advisors acquired a new stake in Integer during the first quarter worth about $30,000. Robeco Institutional Asset Management B.V. acquired a new position in shares of Integer in the 1st quarter valued at $40,000. Financial Gravity Wealth Inc. purchased a new position in Integer in the 1st quarter valued at $45,000. Financial Gravity Companies Inc. purchased a new position in Integer in the 4th quarter valued at $49,000. Finally, PNC Financial Services Group Inc. boosted its position in shares of Integer by 15.8% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,065 shares of the medical equipment provider’s stock worth $81,000 after purchasing an additional 145 shares in the last quarter. 96.00% of the stock is currently owned by institutional investors.
Integer Holdings Corporation operates as a medical device outsource manufacturer worldwide. It operates in two segments, Medical and Non-Medical. The company offers products for vascular, cardiac surgery, and structural heart diseases; peripheral vascular, neurovascular, urology, and oncology products; and electrophysiology, infusion therapy, and hemodialysis products.
Featured Article: Portfolio Manager
Receive News & Ratings for Integer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integer and related companies with MarketBeat.com's FREE daily email newsletter.